You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

335 Results
Drug
Other Name(s): Femara®
Updated
Sep 2025
Drug
Other Name(s): Tykerb®
Updated
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Palliative
Funding:
New Drug Funding Program
    Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph+ BCP-ALL)
New Drug Funding Program
    Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia (Ph- BCP-ALL)
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative
Funding:
New Drug Funding Program
    Blinatumomab - Minimal Residual Disease (MRD)-Positive B-cell Precursor Acute Lymphoblastic Leukemia
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Sep 2025
Drug
Other Name(s): Elrexfio™
Updated
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Sep 2025
Drug
Other Name(s): Trisenox®
Updated
Oct 2025
Drug
Other Name(s): Zinecard®
Updated
Oct 2025
Regimen
Cancer Type:
Gastrointestinal, 
Rectal
Intent: Neoadjuvant
Updated
Oct 2025

Pages